Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients

El-Ghammaz, Amro Mohamed Sedky; Azzazi, Mohamed; Mostafa, Nevine N; Hegab, Hany M.; Mahmoud, Amir

doi:10.1007/s10238-020-00610-x

Cited by 5 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production of GP88 in platelets has not been fully defined, and its production in platelets has not been clarified, but there are reports that there is no correlation between the two even in patients with acute lymphoblastic leukemia. 41 There appears to be no direct relationship between the sGP88 concentrations and thrombocytopenia associated with hepatitis progression.…”

Section: Discussionmentioning

confidence: 98%

Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents

et al. 2021

View full text Add to dashboard Cite

Background: Progranulin (GP88) is an 88-kDa glycoprotein growth factor with important biological effects in tumorigenesis and tumor survival. We investigated the usefulness of measuring serum GP88 (sGP88) levels as a predictive biomarker for hepatocellular carcinoma (HCC) in patients with viral hepatitis C after treatment with direct-acting antiviral (DAA) agents. Methods: We measured the sGP88 levels by using a sandwich enzyme-linked immunoassay from 67 healthy control subjects and 29 patients (20 patients who did not develop HCC and 9 patients who developed HCC after treatment) with viral hepatitis C after treatment with asunaprevir and daclatasvir. Results: The sGP88 levels of patients with chronic hepatitis C prior to antiviral treatment were significantly higher than those of healthy control subjects. After antiviral treatment, the sGP88 levels of patients who eventually developed HCC were significantly higher than those who did not develop HCC. The changes in the sGP88 levels before and after treatment in patients who developed HCC were significantly lower than those in patients who did not develop HCC. The cumulative incidence of HCC was significantly higher in either patients with high sGP88 levels after treatment or those with small changes of sGP88 levels pre- and post-treatment. Conclusions: Sustained high levels of sGP88 in patients treated with DAA agents are correlated with the risk of developing HCC.

show abstract

Section: Discussionmentioning

confidence: 98%

Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 6 Additionally, our group demonstrated recently an association between a high serum PGRN level and an increased relapse risk in adult de novo ALL patients. 7 …”

Section: Discussionmentioning

confidence: 99%

“…However, this study is not in agreement with our other study performed on ALL patients, whose serum PGRN level correlated with an inferior DFS, but not with the OS. 7 This discrepancy can be attributed to the different pathophysiology of AML and ALL. Notably, although the cytogenetic risk category is a well-documented prognostic factor in AML patients, 13 it did not influence the OS in the multivariate analysis of variables in our study.…”

Section: Discussionmentioning

confidence: 99%

“… 6 Moreover, our group proved recently that high serum PGRN level may be used as a predictor of increased relapse risk in adult de novo acute lymphoblastic leukemia (ALL) patients. 7 The aim of the study was to measure levels of PGRN in the serum of adult patients with acute myeloid leukemia (AML) and to correlate its serum levels with prognosis and clinical outcome.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients

Azazzi

El-Ghammaz

Mohamed

2023

Hematology, Transfusion and Cell Therapy

Self Cite

View full text Add to dashboard Cite

“…Furthermore, in a diffuse large B-cell lymphoma, a higher serum GP88 level predicted worsened survival [ 45 ]. In acute lymphoblastic leukemia, an elevated serum GP88 level was not associated with overall survival, but showed a correlation with disease-free survival [ 50 ]. Regarding non-malignancies, in community-acquired pneumonia a higher serum GP88 level was also associated with an earlier patient’s death [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

GP88/PGRN Serum Levels Are Associated with Prognosis for Oral Squamous Cell Carcinoma Patients

Greither

Steiner

Bache

et al. 2021

Biology

View full text Add to dashboard Cite

Progranulin (PGRN)/GP88 is a growth factor that is expressed in a wide range of tumor tissues. The secreted form is involved in various biological processes including proliferation and inflammation. In several tumor types, the serum GP88 level is associated with a patient’s prognosis; however, data for oral squamous cell carcinomas (OSCCs) have not yet been reported. We measured the serum GP88 levels in 96 OSCC patients by an enzyme immunosorbent assay (EIA) and correlated these data with clinicopathological parameters and patient outcomes. The GP88 levels in the serum of OSCC patients and healthy volunteers were comparable. In OSCC patients, the levels did not correlate with age, sex, or TNM status. In a Kaplan–Meier survival analysis, a serum GP88 level < 68 ng/mL was significantly associated with worsened survival (p = 0.0005, log-rank-test) as well as in uni- and multivariate Cox regression analyses (RR = 4.6 [1.6–12.9], p = 0.004 and RR = 4.2 [1.2–12.0], p = 0.008). This effect was predominant in OSCC patients older than 60.5 years (p = 0.027), while in younger patients no significant association between serum GP88 levels and prognosis could be observed. Altogether, lower serum GP88 levels are significantly associated with a worsened outcome for an OSCC and may be an interesting candidate for risk stratification during OSCC therapy.

show abstract

Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients

Cited by 5 publications

References 48 publications

Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents

Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents

Prognostic value of serum progranulin in de novo adult acute myeloid leukemia patients

GP88/PGRN Serum Levels Are Associated with Prognosis for Oral Squamous Cell Carcinoma Patients

Contact Info

Product

Resources

About